Therapeutic combination

Abstract

This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.

Description

[0001] This invention relates to pharmaceutical combinations of amlodipine and pharmaceutical acceptable acid addition salts thereof and atorvastatin and pharmaceutically acceptable salts thereof, kits containing such combinations and methods of using such combinations to subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those additive and synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms or signs of cardiac risk including humans. BACKGROUND OF THE INVENTION [0002] The conversion of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate is an early and rater-limiting step in the cholesterol biosynthetic...

AI Technical Summary

Benefits of technology

"This patent is about a pharmaceutical composition that combines two drugs, amlodipine and atorvastatin, to treat hypertension and hyperlipidemia in one pill. The composition contains a specific amount of each drug and a carrier or diluent. The technical effect of this composition is that it provides greater antihypertensive and hypolipidemic effects than either drug alone, and can be used in combination with other drugs to achieve even greater effects. The composition can be formulated as a tablet or a capsule."

Problems solved by technology

Patients who undergo PTCA or other surgical procedures designed to treat angina pectoris frequently experience complications such as restenosis.

Hypertension frequently coexists with hyperlipidemia and both are considered to be major risk factors for developing cardiac disease ultimately resulting in adverse cardiac events.

For example, hypertension intervention trials have failed to demonstrate full normalization in cardiovascular mortality due to coronary heart disease.

However, these rates are typically less than 10% and rarely exceed 45% in men and 25% in women.

Images